Table 2.
Features of glomerulopathy with homozygous apoE2
| Patient No. | Sex | Age, years | Protein-uria, g/day | sCr at diagnosis, mg/dl | Complications | Therapy | Renal prognosis after diagnosis | Athero-sclerosis | Ref. |
|---|---|---|---|---|---|---|---|---|---|
| 1 | F | 59 | 0.6–8.8 | 1.8 | DM, HT | fibrate, colestyramine, plasmapheresis | sCr 2.2 mg/dl 2.5 years later | none | 6 |
| 2 | F | 00 | 3+ to 4+ | 0.3 | ND | PSL, furosemide, metolazone | sCr 4.2 mg/dl 7.5 years later | none | 7 |
| 3 | M | 12 | 20.3 | 1.1 | anemia | RASI, PSL, CY, FK-506, statin→fibrate | renal failure 1.3 years later | none | 8 |
| 4 | M | 31 | 1.8–4.5 | 1.2 | DM, pan-creatitis | fibrate→statin | ND | none | 9 |
| 5 | M | 41 | 2.8–18.4 | NR | none | PSL, CY, statin and fibrate | no progression 0.7 years later | none | 10 |
| 6 | M | 52 | 3.0–7.5 | 0.8 | none | PSL, aspirin | no progression for 10 years | none | 11 |
| 7 | F | 49 | 2.0–4.0 | 0.5 | HT | fibrate | no progression for 2 years | none | 11 |
| 8 | M | 64 | 1.6–2.1 | 0.9 | DM | RASI, statin, EPA | HD induction 8 years later | CAD | * |
| 9 | M | 58 | 5.0–8.8 | 1.6 | DM, HT | RASI, statin, EPA | HD induction 3 years later | none | * |
| 10 | M | 78 | 1.9–4.2 | 1.1 | DM, HT, hypothyroidism | RSI, statin, ezetimibe | sCR 2.1 mg/dl 2 years later | CAD, CI, PAD | * |
CAD = Coronary artery disease; CI = cerebral infarction; CY = cyclophosphamide; DM = diabetic mellitus; EPA = eicosapentaenoic acid; HD = hemodialysis; HT = hypertension; ND = not described; NR = within the normal range; PAD = peripheral arterial disease; PSL = prednisolone; RASI = renin-angiotensin system inhibitor; sCr = serum creatinine.
*
Current cases.